What it's for (Indications)
- Phenobarbitone is primarily indicated for the management of various seizure disorders, including tonic-clonic (grand mal) seizures, focal (partial) seizures, and status epilepticus.
- It is particularly effective in neonatal seizures and remains a cornerstone in pediatric epilepsy management, especially when other first-line agents are not suitable or effective.
- Beyond its anticonvulsant properties, phenobarbitone has historically been utilized as a short-term sedative-hypnotic for the relief of anxiety or insomnia, and as a pre-anesthetic agent.
- In some specialized cases, its enzyme-inducing properties allow its use in the treatment of cholestasis (e.
- g.
- , in infants with severe unconjugated hyperbilirubinemia) due to its ability to induce hepatic enzymes, facilitating bilirubin conjugation and excretion.
- However, its use for anxiety and insomnia has largely been superseded by agents with a more favorable safety profile, such as benzodiazepines, due to the significant risks of dependence, respiratory depression, and a narrow therapeutic index associated with barbiturates.
- Its potent enzyme induction also makes it valuable in specific genetic disorders like Crigler-Najjar syndrome.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of phenobarbitone is highly individualized and must be carefully titrated based on the patient's age, weight, clinical response, concomitant medications, and serum phenobarbitone concentrations. For the management of epilepsy in adults, typical oral maintenance doses range from 60 mg to 180 mg per day, administered in one to three divided doses. In pediatric epilepsy, the usual oral dose is 3 to 5 mg/kg/day, also given in divided doses, often adjusted based on age and hepatic maturity. For acute management of status epilepticus, an intravenous loading dose of 15 to 20 mg/kg, administered slowly at a rate not exceeding 50 to 100 mg/minute, is often required to achieve therapeutic levels rapidly, followed by appropriate maintenance dosing. As a sedative or hypnotic, lower doses are generally employed; for general sedation, doses typically range from 30 mg to 120 mg per day in 2-3 divided doses, while for insomnia, a single dose of 100 mg to 320 mg at bedtime may be used, though such use is now rare and generally discouraged due to safety concerns. Therapeutic drug monitoring is essential to maintain serum levels within the accepted therapeutic range (e.g., 15-40 mcg/mL for epilepsy) to maximize efficacy and minimize toxicity, especially given the drug's long half-life and potential for accumulation. Dose adjustments are necessary in patients with hepatic or renal impairment. |
Safety & Warnings
Common Side Effects
- Phenobarbitone can produce a wide range of dose-dependent adverse effects, primarily affecting the central nervous system.
- Common side effects include significant sedation, drowsiness, lethargy, fatigue, ataxia (impaired coordination), nystagmus (involuntary eye movement), dizziness, and cognitive impairment, which can significantly affect daily activities, learning, and motor skills.
- In children and some elderly patients, paradoxical hyperactivity or irritability may be observed instead of sedation.
- Less common but serious dermatological reactions, such as severe blistering skin conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported and require immediate discontinuation of the drug.
- Long-term use can lead to bone mineral density reduction, potentially resulting in osteopenia or osteoporosis, and rarely, megaloblastic anemia due to folate deficiency.
- Hepatic dysfunction, including elevations in liver enzymes, can occur, and liver function should be monitored.
- Respiratory depression is a critical and potentially fatal adverse effect, particularly with higher doses, rapid intravenous administration, or when combined with other central nervous system depressants, potentially leading to respiratory arrest.
- Psychological and physical dependence can develop with prolonged use, leading to severe and potentially life-threatening withdrawal symptoms upon abrupt cessation, including status epilepticus, hallucinations, and delirium.
- Cardiovascular effects, such as hypotension, may also occur, especially with rapid intravenous administration.
Serious Warnings
- Black Box Warning: **WARNING: RISK OF DEPENDENCE, WITHDRAWAL, RESPIRATORY DEPRESSION, AND SUICIDAL IDEATION** Phenobarbitone is a barbiturate with a significant potential for physical and psychological dependence. Prolonged use, even at therapeutic doses, can lead to the development of dependence. Abrupt discontinuation or rapid dose reduction, particularly after chronic use, can precipitate severe and potentially life-threatening withdrawal symptoms, including generalized convulsions (status epilepticus), hallucinations, delirium, hyperthermia, and death. Therefore, discontinuation of phenobarbitone must always be gradual, involving a slow, controlled taper over an extended period to minimize the risk and severity of withdrawal. Patients should be informed about the risks of dependence and the importance of adhering to prescribed dosing and discontinuation schedules. Concurrent use of phenobarbitone with other central nervous system (CNS) depressants, including opioids, benzodiazepines, alcohol, and other sedatives/hypnotics, significantly increases the risk of profound sedation, severe respiratory depression, coma, and death. Patients must be educated about these additive depressant effects and strongly warned against concomitant use of alcohol and other CNS depressants without strict medical supervision. Respiratory depression is a dose-dependent risk with phenobarbitone, especially with higher doses or rapid intravenous administration, and can be fatal. Close monitoring of respiratory function is essential, particularly during initiation or dose escalation. Additionally, as an antiepileptic drug (AED), phenobarbitone carries a class-wide warning for an increased risk of suicidal thoughts or behavior (suicidality) in patients taking these medications for any indication. Patients, caregivers, and family members should be closely monitored for the emergence or worsening of depression, unusual changes in mood or behavior, or suicidal ideation. Prescribers should carefully balance this risk with the clinical need for phenobarbitone, particularly in pediatric patients and those with a history of depression or suicidal ideation. Any reported changes in mood or behavior warrant immediate medical evaluation.
- Phenobarbitone carries several critical warnings that necessitate careful patient selection, monitoring, and counseling.
- Respiratory depression is a life-threatening risk, especially with overdose or concurrent use of other central nervous system depressants (e.
- g.
- , opioids, benzodiazepines, alcohol).
- Patients should be advised about the additive depressant effects of alcohol and other sedatives, which can lead to profound sedation, coma, or death.
- Due to its significant CNS depressant effects, phenobarbitone can impair mental and physical abilities required for performing hazardous tasks, such as driving or operating machinery; patients must be cautioned accordingly and advised to avoid such activities until the effects are known.
- Long-term use can lead to physical and psychological dependence.
- Abrupt discontinuation of phenobarbitone, even after relatively short-term use, can precipitate severe and potentially life-threatening withdrawal symptoms, including status epilepticus, hallucinations, delirium, and hyperthermia.
- Therefore, discontinuation should always be gradual, involving a slow dosage taper over weeks or months.
- As with other antiepileptic drugs (AEDs), phenobarbitone carries a class-wide warning for an increased risk of suicidal thoughts or behavior; patients, caregivers, and family members should be closely monitored for new or worsening depression, unusual changes in mood or behavior, or suicidal ideation and immediately report any such observations to a healthcare professional.
- Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), although rare, can be fatal; patients should be advised to seek immediate medical attention for any skin rash, blistering, or mucosal lesions.
- Dose adjustments are crucial in patients with hepatic or renal impairment to prevent drug accumulation and toxicity.
- Phenobarbitone is contraindicated in patients with a history of acute intermittent porphyria as it can exacerbate the condition.
- Caution is advised in elderly or debilitated patients who may be more sensitive to the CNS depressant effects.
How it Works (Mechanism of Action)
Phenobarbitone, a long-acting barbiturate, exerts its primary pharmacological effects by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system. It binds to a distinct allosteric site on the GABA-A receptor complex, which is separate from the benzodiazepine binding site. This binding allosterically modulates the receptor, prolonging the duration of chloride channel opening in response to GABA. The increased influx of negatively charged chloride ions hyperpolarizes the neuronal membrane, making it less excitable and more resistant to depolarization, thereby reducing neuronal firing and neuronal excitability. At higher, supratherapeutic concentrations, phenobarbitone may also directly activate GABA-A receptors even in the absence of GABA, further contributing to its profound CNS depressant and anesthetic effects. Furthermore, phenobarbitone may contribute to its anticonvulsant and sedative actions by inhibiting excitatory neurotransmission through blockade of AMPA receptors (a subtype of glutamate receptor) and voltage-gated calcium channels. A significant aspect of its mechanism is its potent induction of hepatic cytochrome P450 (CYP) enzymes, particularly CYP2C9, CYP2C19, and CYP3A4. This enzyme induction accelerates the metabolism of numerous other co-administered medications, potentially leading to clinically significant drug-drug interactions and reduced efficacy of those drugs, as well as influencing its own metabolism and that of other antiepileptic drugs.
Commercial Brands (Alternatives)
No other brands found for this formula.